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Next Generation Sequencing (NGS) technologies are revolutionizing the diagnostic screening for rare 
disease entities, including primary mitochondrial disorders, particularly those caused by nuclear gene 
defects. NGS approaches are able to identify the causative gene defects in small families and even 
single individuals, unsuitable for investigation by traditional linkage analysis. These technologies are 
contributing to fill the gap between mitochondrial disease cases defined on the basis of clinical, 
neuroimaging and biochemical readouts, which still outnumber by approximately 50% the cases for 
which a molecular-genetic diagnosis is attained. We have been using a combined, two-step strategy, 
based on targeted genes panel as a first NGS screening, followed by whole exome sequencing (WES) 
in still unsolved cases, to analyze a large cohort of subjects, that failed to show mutations in mtDNA 
and in ad hoc sets of specific nuclear genes, sequenced by the Sanger’s method. Not only this 
approach has allowed us to reach molecular diagnosis in a significant fraction (20%) of these difficult 
cases, but it has also revealed unexpected and conceptually new findings. These include the 
possibility of marked variable penetrance of recessive mutations, the identification of large-scale 
DNA rearrangements, which explain spuriously heterozygous cases, and the association of mutations 
in known genes with unusual, previously unreported clinical phenotypes. Importantly, WES on 
selected cases has unraveled the presence of pathogenic mutations in genes encoding non-
mitochondrial proteins (e.g. the transcription factor E4F1), an observation that further expands the 
intricate genetics of mitochondrial disease and suggests a new area of investigation in mitochondrial 
medicine. 
 





Mitochondrial Disorders form a group of rare, genetically and clinically heterogeneous conditions 
characterized by impairment of the mitochondrial respiratory chain, which is responsible for the 
synthesis of most of the ATP in the cells through the oxidative phosphorylation (OXPHOS) pathway. 
Most of the proteins required for the biogenesis, structure and function of mitochondria are encoded 
by genes contained in the nuclear genome (nuclear DNA, nDNA) but 13 essential subunits of four of 
the five canonical respiratory-chain complexes are encoded by a physically separated, semi-
autonomous, genome, the mitochondrial DNA (mtDNA) [1, 2]. Unlike nDNA, which has a diploid 
organization (i.e. two copies) within the nucleus of somatic cells, and a haploid organization (i.e. one 
copy) in gametes, mtDNA is present in multiple copies within the mitochondria of each cell. Human 
mtDNA is a circular, double-stranded molecule, 16,569 base pairs in size, which encodes 37 genes, 
including 22 tRNAs and 2 rRNAs encoding genes essential for mtDNA-specific translation of the 13 
genes encoding as many respiratory chain subunits [3]. Albeit essential for the formation of the 
mitochondrial membrane potential (DP) and ATP production, these polypeptides are outnumbered by 
far by the >75 respiratory chain subunits encoded by nDNA. Overall, it has been estimated that more 
than 1000 nuclear genes encode proteins necessary for mitochondrial maintenance and function, 
including those carrying out mtDNA replication and expression, mitochondrial shape and dynamics 
(fission and fusion), Coenzyme Q10 (CoQ10) biosynthesis and the complex network controlling 
respiratory chain formation, activity and turnover [4, 5]. In principle, all of these genes should be 
considered as potential candidates for mitochondrial disease, and mutations in approximately 200 of 
them have already been established to play a causative role. Nevertheless, most of the mitochondrial 
disease cases, classified on the basis of clinical/biochemical features, still lack a molecular diagnosis 
[6], so as to make the completion of the molecular dissection a compelling need in the diagnostics, 
clinical management, and translational research in mitochondrial medicine. 
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The minimum prevalence of isolated or combined, genetically defined OXPHOS defects is 
approximately 1:5000 live birth, just considering the most recurrent mutations of mtDNA. This figure 
is a very conservative one, as it does not take into account the nuclear gene defects associated with 
mitochondrial disease. A more recent epidemiological survey carried out in Northern UK, which 
includes some frequent nuclear gene mutations, indicates a more realistic, but still underestimated, 
figure of 1:4300 live births [6]. Since the mitochondrial respiratory chain is the final common 
pathway for aerobic metabolism, tissues and organs with high-energy demand based on efficient 
OXPHOS are preferentially involved in mitochondrial disease [7], notably the central nervous 
system, the heart and the skeletal muscle. From a medical standpoint, mitochondrial disorders are 
often suspected on the basis of peculiar clinical presentations, but the diagnostic  workup is often 
complex and difficult, requiring extensive clinical and laboratory evaluation [8]. It can include 
biochemical investigation (e.g. measurement of respiratory chain complex activity and mitochondrial 
oxygen consumption), immunohistochemical , and histoenzymatic analyses, and evaluation of the 
amount and integrity of intact respiratory chain complexes and mtDNA in cultured skin fibroblasts 
or skeletal muscle biopsy; neuroimaging findings; and careful clinical examination and follow-up, 
with several criteria and evaluation scales suitable for either adults [9] or children [10, 11]. 
Unfortunately, the use of different methods and lack of standardized procedures among different 
laboratories worldwide, particularly regarding enzymatic analysis, contribute to make the diagnosis 
even more complicated and uncertain [12]; moreover, not always the affected tissues/organs are 
available for the analysis and fibroblasts, the most easily obtainable cellular model, may not express 
any defect. The gold standard for safe diagnosis is clearly based on the identification of the 
responsible gene. Recent advances in gene screening technologies has become an invaluable tool to 
rapidly analyze know disease genes and to search for mutations in new candidate genes. 
This paper reports our own experience on how the development of Next Generation Sequencing 
(NGS) approaches has in fact substantially improved the efficiency of mutation discovery and 
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facilitated its translation into routine diagnostics of mitochondrial disease, with remarkable 
advantages in terms of diagnostic score, and increased value for money and time consumed [13]. 
NGS includes a series of techniques that enable automation of nucleic acids (RNA and DNA) 
sequencing, increasing the analysis power from a few hundred base pairs to the entire genome in a 
single run. NGS became available to the genetics community in 2008–09 when the first NGS 
machines entered the market [14]. The process required for NGS to implement research or diagnostic 
procedures comprises a wet laboratory workflow, including the preparation and sequencing of 
libraries from individual DNA samples. This step is followed by a post-sequencing workflow 
involving informatics and bioinformatics analyses performed to align the sequences, and call, 
annotate and filter the variants. This analytical in silico step is crucial to identify and distinguish rare 
causative mutations from hundreds of frequent or non-pathogenic sequence polymorphisms. Upon 
completion of this pipeline the selected variants can be either known pathogenic mutations or novel 
candidate changes. In general, the first option is followed by a review of the literature in order to 
establish/confirm a causative phenotype-genotype association. As for the second option, the 
conclusive demonstration of the pathogenic role of a given variant will depend on additional 
experimental validation. For instance, the detection of mutations in the same gene in unrelated 
individuals or families with a similar phenotype is a robust and relatively straightforward genetic 
validation. But when only one case/family is available for genetic analysis, then the pathogenic role 
of a suspected variant must be confirmed by functional studies focused on the evaluation of its 
biological effects [13]. In mitochondrial disease, the availability of mutant cells from patients  is 
important to assess the presence of a biochemical defect affecting the OXPHOS system, and as a 
source of mRNA and proteins for further experimental validations. In addition, cells are essential to 
carry out complementation assays and evaluate the rescue of the phenotype under expression of the 
recombinant wild-type cDNA introduced by transfection or viral transduction [15, 16, 17]. However, 
this procedure is applicable only to those conditions in which a specific readout, usually biochemical 
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(e.g. activities of individual respiratory-chain complexes, oxygraphic studies, CoQ measurement) but 
sometimes also morphological (e.g. structure of the mitochondrial network, apoptotic nuclei, etc.) 
can be detected in cultured cells (typically fibroblasts, sometimes myoblasts). In other cases, for 
instance for genes with an ortholog in Saccharomyces cerevisiae, mutations can be modeled in a yeast 
system. A number of biochemical OXPHOS defects, however, are poorly or hardly expressed in 
cultured cells and involve recent genes (not conserved in yeast). In these cases, a functional 
complementation approach is difficult, and validation largely relies on the identification of unrelated 
cases with mutations in the same gene and displaying a similar phenotype. For many genes causing 
mitochondrial disease, the small number of reported cases makes it difficult to safely establish a 
consistent clinical and neuroimaging nosography. Although some peculiar genotype-phenotype 
associations have been reported, these observations may be based on an inclusion bias, because once 
a mutant gene is found in a single or just a few subjects, then the clinical and neuroimaging features 
are often exploited to identify additional patients. Indeed, thanks to unbiased NGS approaches, very 
different clinical presentations have recently been reported in patients harboring mutations in the 
same gene (e.g. AARS2, AIFM1) [18, 19]. 
In the present study, we analyzed a heterogeneous cohort of 125 patients diagnosed as affected by 
mitochondrial disease, mostly characterized by early onset. Using a combined NGS approach based 
on a targeted gene panel and whole exome sequencing (WES), we genetically screened our cohort of 
mitochondrial disease patients in order to: widen the spectrum of clinical presentations associated 
with genes already known to cause MD; discover causative mutations in new candidate genes never 
associated to MD before; evaluate the power of NGS in identifying mutations in patients negative to 





2. MATERIALS AND METHODS 
2.1 Clinical and biochemical investigation 
125 patients (60 males and 65 females; 78 with age of onset ≤1, the mean onset of the remaining ones 
was 18.6 years) referred to the Neurological Institute “C. Besta” (Milan, Italy) and diagnosed as 
affected by mitochondrial disease through the integration of clinical, biochemical and morphological 
investigations were enrolled in this study and coded as NGSP001-NGSP125. Histological analyses 
and measurements of respiratory chain and pyruvate dehydrogenase (PDH) complex activities were 
performed according to standard procedures [16, 20]. Based on the biochemical profile and mtDNA 
characterization obtained in either fibroblasts, skeletal muscle, or both, patients were divided into 
different groups as follows: defects in complex I (n. 5), complex II (n. 18), complex III (n. 15), 
complex IV (n.21), complex V (n. 5), multiple defects (n. 26), CoQ10 deficiency (n. 3), mtDNA 
multiple deletions and/or depletion (n. 8) and PDH complex activity (n. 14) (Supplementary table 
S1). In 8 subjects the biochemical analysis was not performed because no biological material was 
available, and in two no biochemical respiratory chain defect was assessed, but they were all included 
in the study since the clinical and/or neuroimaging features were highly suggestive for a 
mitochondrial disease. Notably, complex I deficient patients are underestimated in this cohort because 
most of them were already analyzed in previous genetic studies [21, 22]. The clinical diagnosis is 
also included in supplementary table S1; a detailed clinical description for NGS091 is reported as 
supplementary material. All patients had previously been screened by traditional Sanger’ sequencing 
for mtDNA mutations, and for sets of genes associated with the specific biochemical or molecular 
(mtDNA) defect and/or clinical presentation, and in no case were mutations found as suggestive for 
a pathogenic role. 
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Informed consent for genetic studies was obtained from all investigated subjects in agreement with 
the Declaration of Helsinki. 
 
2.2 Molecular genetics 
Our combined NGS approach was first based on analysis of our entire cohort of 125 individuals by a 
custom-made targeted mitochondrial panel of 132 genes (Supplementary table S2). Next, we selected 
for WES ten samples, which were negative for the genes contained in the panel. 
2.2.1 Custom-made targeted gene panel  
Genomic DNA was extracted from peripheral blood. We used 250 ng of DNA as template for the 
construction of a paired-end library, according to the TruSeq Custom Amplicon Library preparation 
guide (Illumina). Sequencing was performed on an Illumina MiSeq platform. We sequenced a custom 
panel of genomic regions corresponding to the transcribed sequences of 132 genes (exons and UTR 
regions), selected to be already associated with mitochondrial disorders or to be candidate genes that 
take part to the same molecular pathways. The sequencing reads were aligned to the NCBI human 
reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA). Single nucleotide 
variants (SNVs) and small insertions/deletions (INDELs) calling was performed using the Somatic 
Variant Caller (Illumina); Variant Studio software (Illumina) was used for variants annotation and 
filtering. Filtering was carried out by applying a series of steps: low-quality variants were filtered out 
(Illumina Qscore threshold of 30); variants with a minor allele frequency (MAF) >1% in the 1000 
Genomes Project (http://www.1000genomes.org) and Exome Variant Server databases 
(http://evs.gs.washington.edu) were discharged. Finally, we focused on predicted missense, frame-
shift, stop-gain or stop-loss, and splice-site variants. For remained variants in the final list we also 
checked their frequency in the Exome Aggregation Consortium (ExAC) database.  
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2.2.2 Whole Exome Sequencing 
WES analysis was conducted using 50 ng of DNA as template for the construction of pair-ended 
libraries with the Nextera Rapid Exome Capture kit (Illumina), following the manufacturer’s 
instructions. Sequencing was performed on 12 pM libraries with the addition of 1% 12.5 pM PhiX 
control library on an Illumina MiSeq platform. Libraries were run several times until 12-15 G of 
data/sample were obtained. Sequences from the FASTAQ files were aligned to the human genome 
(hg19) by using the BWA aligner. Variants were called by using the GATK HaplotypeCaller, and 
then filtered by using the Variant Quality Score Recalibration according to the best practices of 
GATK-2.7 (https://www.broadinstitute.org/gatk/). Variants were annotated by using Annovar. 
Coverage of the targeted regions was estimated using the GATK DepthOfCoverage. For paired end 
reads to be included, they needed to have a mapping quality greater than 20 and a base quality greater 
than 10. 
In addition to the standard SNVs and small INDELs annotation and filtering process, the presence of 
larger insertions/deletions as well as copy number variations (CNVs) was assessed through a deeper 
analysis of NGS coverage data. Using the cn.MOPS software publicly available as an R package 
(http://www.bioinf.jku.at/software/cnmops), we analyzed both targeted gene panel sequencing and 
WES dataset bam files. Using a Bayesian approach, cn.MOPS decomposes variations in the depth of 
coverage across samples into integer copy numbers and noise by means of its mixture components 
and Poisson distributions, respectively [23]. 
Variants identified by NGS were validated by Sanger’ sequencing. The chromatogram traces were 
analyzed using the Sequencher software (Gene Codes Corporation). mtDNA content was evaluated 
by real-time PCR-based quantification (ABI7000 Real-Time PCR System) using specific mtDNA 
probes and a standard, single-copy autosomal gene (RNaseP) [16]. RNA was extracted from skin 
fibroblasts and 1 μg was used as template for reverse transcriptase PCR (RT-PCR) to obtain full-
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length cDNA. Transcripts of candidate genes were amplified through PCR and run by electrophoresis 
through a 1% agarose gel in order to detect potential splicing alterations. PCR products were also 
sequenced in order to confirm genomic variants and unmask potential events of nonsense-mediated 
decay. Real-time quantitative PCR (qPCR) was performed on retro-transcribed cDNA from 
fibroblasts of patients and controls, using an ABI Prism 7000 apparatus (Applied Biosystems). The 





3.1 Targeted gene panel 
Since the majority of our cohort was composed of patients showing an autosomal recessive mode of 
disease inheritance, we focused our search on homozygous and compound heterozygous variants, 
although in a smaller set of individuals the mode of inheritance was uncertain or compatible with 
autosomal dominant or X-linked transmission. In these cases, single heterozygous variants were also 
considered. In addition, for samples with recessive inheritance but presenting just one heterozygous 
variant in a likely gene candidate, we performed extended systematic NGS coverage analysis in 
search of a second allelic variant. This analysis was carried out by looking for: 1) regions not covered 
or poorly covered by NGS, which were then analyzed by Sanger’ sequencing; 2) large heterozygous 
deletions involving entire exons using the cn.MOPS software, followed by cDNA amplification and 
sequencing to investigate the effect of the two variants on the gene transcript(s); 3) quantitative or 
qualitative cDNA abnormalities due to variants within intronic or regulative regions not targeted by 
NGS (Fig. 1). 
The targeted gene panel allowed us to analyze both the coding sequences as well as the 5’ and 3’ 
untranslated regions of 132 genes, for a total of 1078 exons (2565 amplicons). The total amount of 
the targeted genomic regions is 338K bp and an average number of 249625 reads were produced per 
sample, allowing us to reach an average depth of coverage of 228X per sample. With our pipeline we 
called an average number of 311 variants per sample (SNVs and INDELs). 
After performing variants annotation and filtering steps, we were able to identify the causative 
mutations of the disease in 19 patients (15.2%), whereas in 27 additional cases we found candidate 
variants that were considered likely but not conclusively causative (Supplementary table S1). Of the 
19 patients with an ascertained causative mutation, 2 were patients with defective complex I, 2 with 
defective complex II, 2 with defective complex III, 2 with defective complex IV, 2 with defective 
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PDH complex, 6 with multiple defects, 1 with mtDNA depletion whereas 2 were biochemically 
undefined (Table 1, Fig. 2). 
Of the patients with ascertained or likely recessive inheritance, 7 carried homozygous mutations 
within the DLD, SDHB, ACAD9, TTC19, LYRM7, NDUFV1 and RNASEH1 genes, whereas 5 carried 
compound heterozygous mutations within the TSFM, FBXL4, RARS2, MRPL44, and NDUFS3 genes. 
Two male subjects carried hemizygous mutations, causing amino acid missense substitutions, within 
the AIFM1 and PDHA1 genes, both localized on the X chromosome (Table 1).  
The identified variants comprised already known causative mutations [24-27], variants that we have 
experimentally validated in dedicated studies [17, 28, 29], or predicted pathogenic variants in genes 
responsible for mitochondrial disorders with a phenotype overlapping the clinical presentation 
observed in our mutant subjects. Concordance between genotype and phenotype helped us to achieve 
definite molecular diagnosis. In order to validate all the variants discovered and their segregation with 
the disease, we performed Sanger’ sequencing on the DNA of the probands and of all the available 
family members. Interestingly, this analysis allowed us to demonstrate reduced penetrance for a 
homozygous variant identified in the SDHB gene in two sisters, the older of whom showed hardly 
any symptoms, whereas the younger (NGSP124) was affected by severe mitochondrial 
leukoencephalopathy; this family is described in detail by Ardissone et al [28].  
By performing NGS coverage analysis we were also able to identify the causative mutations in three 
additional patients who were negative after the variants-filtering pipeline. In one case (NGSP018) a 
single heterozygous SNV was identified within the MTFMT gene, then coverage analysis revealed a 
non-covered region within exon 1 of the same gene. Sanger’ sequencing showed the presence of a 
second, nonsense heterozygous, allelic mutation in this region. In the second case (NGSP100) we 
found a heterozygous missense mutation in DARS2 in a patient with a neuroimaging pattern highly 
suggestive for DARS2-related leukoencephalopathy. Coverage analysis revealed a heterozygous 
deletion encompassing the last two exons of DARS2. Sequencing of the cDNA obtained from patient’s 
fibroblast RNA showed only the presence of the allele with the missense mutation. Accordingly, 
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Western-blot analysis on whole cell lysates of primary patient’s fibroblasts revealed a clear reduction 
of DARS2 protein amount compared with controls. In the third case (NGSP122) no SNV or small 
INDEL were identified through variants analysis, but coverage analysis allowed us to detect a 
homozygous large deletion involving the entire DNAJC19 gene, which was then confirmed by 
Sanger’ sequencing.  
For cases with a family history clearly supporting dominant inheritance or for sporadic cases with 
mutations in genes known to be associated with an autosomal dominant trait, we also evaluated genes 
with heterozygous variants. We identified one subject (NGSP098) with a heterozygous mutation 
within the POLG gene, which was also present in two additional affected subjects of the family and 
already reported in a patient with myopathy [30]. A second female patient (NGSP031) carried a 
heterozygous mutation of the X-linked PDHA1 gene, already described in females with defects of the 
PDH complex [31]. We also found 6 additional heterozygous missense SNVs within genes previously 
associated with dominantly inherited mitochondrial disease: three SNVs in POLG and one each in 
DNA2, MFN2 and OPA1. However, these findings were not considered conclusive because of either 
discordance with the phenotype typically associated with mutations in these genes [32, 33], uncertain 
or no pathogenicity of the SNV according to the literature [34, 35], or no segregation with the disease 
(Table 1). 
 
3.2 Whole exome sequencing 
From the group of patients that failed to attain conclusive genetic diagnosis after targeted gene panel 
NGS, we selected 10 patients for WES, based on accuracy of family history and clinical description, 
parental consanguinity, availability of DNA samples from other family members, suggestive and 
peculiar phenotypic features and well-established disease inheritance These patients included 3 cases 
with defects in complex IV activity, 2 cases with mitochondrial multiple defects, 3 cases with defect 
of PDH complex activity, 1 patient with mtDNA depletion and 1 patient with no biochemical 
diagnosis available, but with an affected sibling and an MRI pattern suggestive for a mitochondrial 
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encephalopathy. WES allowed us to analyze the transcribed regions of the 99.9% of genes present in 
the human genome, for a total of ~60 Mb. The average number of reads produced per sample was 
~59 millions, with an average number of bases with a coverage greater than 20x of 91.6±4.6 %. With 
our pipeline we called an average number of 377±48 variants per sample. Most of the variants were 
non-synonymous SNVs in the coding regions (359±35.2), including stop gain mutations (7.8±1.5), 
but a small proportion of INDELs were also detected (14±3.0). 
After performing variants annotation and filtering steps, we were able to identify causative mutations 
in six patients (60%) (Table 2). Four unrelated patients were born from consanguineous parents and 
carried homozygous mutations in different genes: PC, CYP2U1, PREPL and E4F1. In a fifth patient, 
two allelic heterozygous mutations were identified in a putative assembly factor for complex IV. In 
a sixth patient, a single heterozygous missense mutation was found in RANBP2, inherited from the 
mother. Notably, only the protein encoded by the PC gene, pyruvate carboxylase, and the putative 
assembly factor specific to complex IV are proteins exclusively and specifically targeted to 
mitochondria, whereas the other genes encode polypeptides that are localized and operate outside the 
organelle.   
Pyruvate carboxylase is a biotin-dependent mitochondrial enzyme, which converts pyruvate into 
oxaloacetate in the first step of gluconeogenesis. Pyruvate carboxylase deficiency (OMIM #266150), 
due to mutations in the PC gene, is associated with three clinical forms of different severity and 
outcome [36-38]. Our patient (NGSP067) displayed a severe condition characterized by psychomotor 
delay and tetraparesis with leukoencephalopathy, associated with biochemical defects of complexes 
I and III of the mitochondrial respiratory chain. The presence of the same variant also in the affected 
sister and a concordant phenotype/genotype association confirmed this homozygous mutation as the 
cause of the disease. However, it is not clear the link between PC mutation and the respiratory chain 
deficiency (observed in muscle but not in fibroblasts from NGSP067) or if the latter could be a 
secondary effect caused by impairment in pyruvate metabolism.  
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The two compound heterozygous mutations in a gene encoding a putative mitochondrial assembly 
factor specific to complex IV were found in a child (NGSP073) with defects in complex IV activity, 
associated with peripheral neuropathy, hypotonia and a cavitating leukoencephalopathy. According 
to the literature, no mutations of this gene have been linked to any pathological condition so far. 
Mutations and function of this protein are currently under study. 
As for mutations in non-mitochondrial gene products, in a patient (NGSP065), born from 
consanguineous parents, presenting with reduced PDH complex activity, hyperlactacidemia, spastic 
paraparesis and white matter MRI alterations, targeted gene panel NGS showed the presence of a 
single heterozygous missense variant within the KARS gene, encoding the lysyl-tRNA synthetase 
common to both cytosol and mitochondria. Mutations in this gene are reported to cause Charcot-
Marie-Tooth disease, recessive intermediate, B (CMTRIB, OMIM #613641) with an essentially 
recessive mode of inheritance [39]. This fact and the clear consanguinity of the parents prompted us 
to deem this variant as non-causative. Conversely, WES analysis revealed a homozygous deletion of 
13 nucleotides involving the splicing site of exon 3 in the CYP2U1 gene, encoding a member of the 
cytochrome P450 superfamily. CYP2U1 is mutated in autosomal recessive spastic paraplegia 56, 
(OMIM #615030). By comparing our case with the clinical presentations described in the literature, 
an overlapping spectrum of symptoms emerges, strongly suggesting a causative link between our 
genetic findings and the biochemical and clinical features of the patient. Interestingly, mutations in 
CYP2U1 have been reported to alter mitochondrial architecture and bioenergetics [40]. 
In a patient (NGSP066) born from consanguineous parents, with defective complex IV activity, 
psychomotor delay, somatic growth retardation and myopathy with neonatal onset, the targeted gene 
panel NGS screening revealed a heterozygous variant within the OPA1 gene. This variant was not 
considered conclusive, because of the marked inconsistencies between the clinical presentation of our 
patient and the phenotypes reportedly associated with OPA1 dominant mutations. No homozygous 
mutations were found by WES but further analysis of raw data revealed a large, completely non-
covered DNA region, spanning from exon 6 to exon 14 of the PREPL gene, suggesting an intra-genic 
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homozygous deletion, This finding was subsequently confirmed by Sanger’ sequencing. PREPL 
belongs to the propyl oligopeptidase subfamily of serine peptidases and large deletions involving also 
this gene have been associated with hypotonia-cystinuria syndrome, also known as the 2p21 deletion 
syndrome (OMIM #606407) [41]. In addition, Parvari et al. described seven patients affected by 
cystinuria and mitochondrial disease with a large deletion on chromosome 2p16 involving the 
SLC3A1 gene, known to cause isolated cystinuria type 1, the PP2Cbeta gene and the PREPL gene 
[42]. Recently, PREPL deficiency has been associated with a congenital myasthenic syndrome with 
growth hormone deficiency [43], resembling the clinical presentation of our patient. No specific 
studies have been performed so far to assess any direct effect of PREPL defects on mitochondrial 
function; alternatively, the complex IV deficiency found in our patient could be a secondary finding, 
due to muscle dysfunction. 
In a patient (NGSP091) presenting with reduced PDH complex activity, hypotonia, growth delay, 
microcephaly, hyperlactacidemia and organic aciduria, Brain MRI revealed the presence of 
symmetric necrotic lesions in the subthalamic nuclei and substantia nigra, suggestive for a diagnosis 
of Leigh disease (Fig. 3A). A detailed clinical description of this case is reported as supplementary 
data. WES revealed a homozygous missense variant within the E4F1 gene (E4F transcription factor 
1), affecting a highly conserved amino acid residue (Fig. 3B). The E4F1 gene variant was 
homozygous also in an affected sibling whereas the two parents were heterozygous (Fig. 3C). E4F1 
encodes a multifunctional zinc finger protein, which acts as an atypical ubiquitin E3 ligase for p53 
[44] and, as a transcriptional factor, regulates the expression of several genes involved in 
mitochondrial functions and cell-cycle checkpoints [45]. We then tested the transcript levels of some 
genes regulated by E4F1 by qPCR. According to Rodier et al [45], the genes whose expression is 
clearly activated by E4F1 are, DNAJC19, encoding a mitochondrial protein; DLAT and PDPR, two 
genes encoding proteins related to the PDH complex; and CHEK1, the major component of the 
CHK1-Dependent Checkpoint of the cell cycle. Interestingly, we observed that all these transcripts 
were reduced in patient’s fibroblasts compared to controls (Fig. 3D): DNAJC19 was the most affected 
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(46%; P<0.001); CHEK1, DLAT and PDPR showed partial but significant reductions (P<0.05). Given 
this biological evidence, as well as the rarity and predicted pathogenicity of the E4F1 variant, we 
strongly suggest a causative involvement of the mutated E4F1 gene in the disease.  
Finally, in a patient (NGSP110) with combined defects in respiratory chain complexes III and IV and 
in the PDH complex, presenting with two episodes of acute encephalopathy concomitant with fever, 
no pathogenic mutations were found by targeted gene panel NGS, and WES failed to identify any 
candidate amongst the recessive variants. However, we detected a known heterozygous mutation in 
the RANBP2 gene, which encodes Ran-Binding Protein 2, a component of the nuclear pore complex 
playing a role in nuclear protein trafficking, sumoylation of protein cargoes, intracellular trafficking 
and energy maintenance [46]. This mutation has already been associated with “Susceptibility to acute, 
infection-induced encephalopathy 3” (OMIM #608033), a dominantly inherited condition 
characterized by acute necrotizing encephalopathy following a febrile illness [46-48]. Notably, the 
mutation in our patient was inherited from his mother, who is now asymptomatic but reported an 
acute episode of encephalopathy at 6 years of age, requiring Intensive Care Unit admission, during a 




In this study we applied a combined NGS approach based on targeted gene panel sequencing and 
WES, to analyze 125 patients with a suspect of mitochondrial disease, who had previously been 
screened with traditional Sanger’ sequencing for the entire mtDNA and for specific sets of genes 
known to be associated with the mitochondrial defect and/or the clinical presentation of each subject. 
This strategy let us achieve uncontroversial genetic diagnosis in 19 patients (15.2%) by targeted gene 
panel sequencing and in 6 out of 10 (60%) by WES. Our results demonstrate the power of this 
combined NGS strategy to achieve genetic diagnosis in several cases, who had failed to be solved by 
Sanger’ sequencing based screening of specific genes.  
Since the targeted gene panel includes almost all the known genes associated with mitochondrial 
disease and usually analyzed through Sanger’ sequencing, which has an average discovery rate of 
about 10% [49], we estimate a diagnostic success of the NGS panel approach of ≈25%, when used as 
a first screening strategy. This figure is clearly much higher than the traditional candidate gene 
approach based on Sanger’ sequencing.  
Importantly, the unbiased, simultaneous analysis of a huge number of genes increases the heuristic 
value of the investigation, allowing the discovery of new, unexpected genotype/phenotype 
associations. Although for this scope WES is clearly more powerful, as it enables the discovery of 
novel mitochondrial disease-linked genes, targeted gene panel NGS is also a valuable tool, as it can 
widen the spectrum of the clinical presentations associated with known disease-associated genes. For 
example, the hemizygous mutation in the X-linked AIFM1 gene, found in one of our male patients, 
was associated with predominant reduction of complex IV activity, a muscle biopsy already 
pathological at 13 years of age, with evidence of chronic denervation, ragged-red fibers, and 
cytochrome c oxidase negative or hyporeactive fibers, and a neuromuscular syndrome of moderate 
clinical severity [19]. These features markedly differ from previously reported cases of AIFM1 
mutations, which were associated with a spectrum of conditions, from Cowchock syndrome 
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(CMTX4, Charcot-Marie-Tooth disease with deafness and mental retardation, OMIM #310490), 
caused by a single AIFM1 founder mutation, to early onset, severe or extremely severe 
encephalomyopathy, with multiple respiratory-chain defects, and partial mtDNA depletion 
(Combined Oxidative Phosphorylation deficiency 6, COXPD6, OMIM #300816).  
On the other hand, the intrinsically unbiased approach of WES requires a deeper variants analysis, 
which is more complex than that required for targeted panel NGS, and must be integrated with 
available clinical, metabolic, neuroimaging and biochemical data. Further functional (experimental) 
validation is usually necessary to demonstrate the biological consequences of the mutations and their 
direct causative role in disease. Thus the availability of biological samples (muscle biopsy, 
fibroblasts, etc) is extremely important. Although these new high-throughput genetic approaches can 
be applied to large cohorts of poorly characterized patients, the knowledge about a specific 
biochemical defect present in a sequenced subject could be extremely useful to support the filtering 
process in order to select the causative variant. Moreover the presence of a biochemical phenotype 
allows confirmation of variant pathogenicity by complementation studies. 
In five out of the ten subjects who underwent WES, we were able to identify the causative mutations 
and in a sixth one we found a strong candidate variant (in E4F1). Notably, only in 2 cases have the 
mutant proteins been demonstrated to exclusively target to mitochondria (PC and a putative complex 
IV assembly factor). In the remaining cases the responsible genes (CYP2U1, PREPL, RANBP2 and 
E4F1) encode proteins not localized into mitochondria, whose functional relation with mitochondrial 
OXPHOS is unknown, unclear or not exclusive [40, 45].  
Thus, a fraction of subjects initially classified as mitochondrial-disease patients may indeed carry 
mutations in genes encoding proteins not targeted to mitochondria, and playing roles not obviously 
related to mitochondrial physiology, despite the presence of clinical and biochemical features 
supporting mitochondrial dysfunction. This may well account for a still unknown percentage of 
genetically unsolved cases classified as mitochondrial disease on the basis of biochemical, clinical or 
morphological findings. The relatively loose link demonstrated by our WES results between 
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biochemical features and genetic basis of disease is likely due to the central role of mitochondria in 
a huge number of cellular pathways, although the exact molecular mechanisms of these apparently 
spurious or possibly indirect associations is far from being clarified [50]. A potentially interesting 
and conceptually novel finding concerns the mutation in E4F1, which, to our knowledge, is the first 
example of a transcription factor involved in the orchestration of gene expression related to 
mitochondrial bioenergetics to cause a biochemically defined mitochondrial condition (PDH complex 
deficiency). Interestingly, a region of E4F1 (aa 30–80) required for its Ub E3 activity presents 
sequence similarities with IR domains of the SUMO E3 ligase RanBP2, and it has been proposed that 
E4F1 and RanBP2 E3 domains may originate from a common ancestor [44]. More work is warranted 
to validate the pathogenic role of the mutation and establish a pathomechanistic link between 
defective E4F1 and PDH deficiency. We have obtained evidence strongly suggesting the attractive 
possibility that the biochemical and clinical features associated with the E4F1 mutation are the 
consequence of the direct role of E4F1 in the expression of gene products, which are part of or play 
a regulatory role on pyruvate dehydrogenase. Two relevant genes have been shown to contain an 
E4F1 binding site near the promoter region [45]. The first is DLAT, encoding dihydrolipoamide S-
acetyltransferase, the E2 component of the PDH complex. Dihydrolipoamide acetyltransferase, 
accepts acetyl groups formed by the oxidative decarboxylation of pyruvate and transfers them to 
coenzyme A. Mutations in this gene are also a cause of pyruvate dehydrogenase E2 deficiency 
(PDHDD, OMIM #245348) which causes primary lactic acidosis in infancy and early childhood. The 
second gene is PDPR, which encodes the pyruvate phosphatase regulatory subunit. PDPR subunit 
combines with a catalytic subunit, encoded by the PDP2 gene, to form a pyruvate dehydrogenase 
phosphatase heterodimer. A second PDH phosphatase is a monomeric enzyme encoded by PDP1, 
which retains both regulatory and catalytic domains. Altogether, these PDH phosphatases are the 
main activator of the complex, and mutations in PDP1 are associated with PDH complex deficiency 
(OMIM #608782) [51, 52]. In patient’s fibroblasts we found a reduction in the expression of both 
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DLAT and PDPR; although the decrease is not striking, it is concordant with the results obtained in 






In summary, NGS strategies offer a wide range of approaches to screen patients with suspected 
mitochondrial disease, including targeted gene panel sequencing, comprehensive mitochondrial gene 
panel [53], clinical exome panel (~4.000 clinically relevant genes) and WES. The choice of which 
technique may be the most suitable for genetic investigation of these disorders depends on several 
factors, such as availability of funding, space, personnel and bioinformatics expertise.  
In our opinion, a two-step approach based on targeted gene panel NGS, followed by WES analysis 
for patients negative to the former screening, combines high diagnostic score with affordability of 
costs within an acceptable timeframe. The custom-made targeted panel sequencing allows the 
screening of large cohorts of patients with relatively easy and manageable interpretation of post 
sequencing data. WES has been used at a second level, as an unbiased, and more exhaustive approach, 
to further screen a selected subgroup of patients leftover after targeted panel sequencing. In these 
selected cases, it was not surprising that the responsible gene would indeed be likely to encode 
proteins less directly linked to mitochondrial bioenergetics, or for which a specific biological role has 
not yet been fully elucidated. 
Finally, we want to underscore that the identification of a likely candidate gene or mutation is often 
the beginning of a complex process aimed at validating the pathogenic role of the mutant variant and, 
in several cases, the very function of novel gene products or proteins previously not considered as 
mitochondrial. In vitro studies on isolated mutant and wild-type proteins, mutant cell characterization, 
modeling in yeast or other in vivo systems, including different animal species, are part of the 
experimental package available to translational research to contribute to expand medical knowledge 
on mitochondrial disease and their scientific relevance to understand the complex biology of 
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Figure 1. Flowchart of the genetic analyses 
Schematic representation of the different steps of the Next Generation Sequencing (NGS) data 
analysis used in this study. Checkered flags indicate the achievement of a defined molecular 





Figure 2. NGS genes panel analysis 
Histograms reporting the patients analyzed by the NGS panel, classified according to their 
biochemical defect (A) and the percentages of patients with a molecular diagnosis in each class (B). 
cI, cII, cIII, cIV, cV: complex I, II, III, IV, V defect; CoQ: CoQ10 deficiency; mtDNA alt: mtDNA 
depletion or deletions; multi: multiple RC complex defect; PDH: pyruvate dehydrogenase complex 
deficiency; Neg: patients with no biochemical deficiency. Colors indicate subjects with (blue) or 





































































Figure 3. Clinical and molecular analysis on the E4F1 mutant patient 
(A) Brain MRI: T2 transverse brain sequences showing symmetric lesions in subthalamic nuclei 
(panel I, arrowhead) and substantia nigra (panel II, arrowhead). (B) Pedigree of the family and 
electropherograms of the E4F1 region containing the c.430A>C variant. Black symbols indicate 
clinically affected subjects. (C) Human E4F1 contains three domains: an ubiquitin E3 ligase-like 
domain that may mediate ubiquitination of chromatin-associated p53, a domain containing three 
C2H2 zinc-finger motives required for DNA binding and also involved in protein dimerization and a 
domain containing six C2H2 zinc-finger motives involved in DNA binding. Phylogenetic alignment 
of the human protein region containing the substitution found in affected individuals is shown below 
along with representative protein regions from placental and marsupial mammals, birds and reptiles, 
where this gene is present. The conserved residue mutated in affected individuals is boxed in red. (D) 
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Transcript levels of E4F1 target genes in fibroblasts from NGS091 (pt) and controls (ct), measured 
by qPCR. Data represent the mean ± SD of four experiments. ***: p<0.001, **: p<0.01 and *:p<0.05 
by unpaired two-tailed Student’s t test. 
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Table 1: Variants identified by the NGS panel 
Code Biochemical defect Gene Mutations 
Exonic 




NGSP36 cI NDUFS3 p.R140P+p.R199W / AR Parents: Heterozygous <0,01%   
NGSP109 cI NDUFV1 p.R386C homoz / AR Parents: Heterozygous 0,012% [24]a 
NGSP124 cII SDHB p.D48V homoz / AR Incomplete penetrance <0,01% [28]b 
NGSP21 cII PDHA1  p.S388P hemiz / X   Ø   
NGSP92 cIII TTC19 p.Q261Gfs*8 homoz 
/ AR Parents: Heterozygous Ø [29]b 
NGSP113 cIII LYRM7 p.D25N homoz 
/ 
AR Parents: Heterozygous Ø [25]a 
NGSP90 cIV RARS2 p.M1V+p.S443P / AR   0,012%;<0,01%   
NGSP100 cIV DARS2 p.L10P hetero ex. 15-16 AR Mother: p.L10P hetero Ø   
NGSP70 mtDNA depl FBXL4 p.C547*+p.Q404* / AR Parents: Heterozygous 0,015%;Ø   
NGSP118 multi RNASEH1 p.V142I homoz / AR 3 homozygous siblings <0,01% [17]
b 
NGSP117 multi TSFM p.G183S+ss(c.232-3C>G)  / AR Altered splicing Ø;<0,01%   
NGSP35 multi MRPL44 p.L156R+p.K278* / AR   0,028%;Ø [26]a 
NGSP122 multi DNAJC19   All exons AR       
NGSP018 multi MTFMT p.S209L+p.Q25* / AR   0,036%;Ø [27]a 
NGSP38 multi AIFM1 p.G262S hemiz / X Mother: heterozygous Ø [19]b 
NGSP33 PDH DLD p.R482G homoz / AR   Ø   
NGSP31 PDH PDHA1 p.R127Q heteroz / X Affected female Ø [31]a 
NGSP023 nd ACAD9 p.R414C homoz / AR Mother: heterozygous <0,01%   




Probably non-pathogenic variants 
NGSP60 multi POLG p.Y831C heteroz /   




NGSP1 PDH POLG p.G517V heteroz /   Reported as benign SNP 0,47% [34]a  
Unlikely causative variants 
NGSP48 multi POLG p.R628W heteroz /   Different phenotype <0,01%   
NGSP12
1 nd DNA2 p.A633S heteroz /   Different phenotype <0,01%   
NGSP66 cIV OPA1 p.T95M hetero /   Different phenotype; PREPL deficiency by WES 0,017% [32]
a 
NGSP86 cIV MFN2 p.R250Q hetero /   Different phenotype 0,029% [33]a  
AR: autosomal recessive; AD: autosomal dominant; X: X-linked. Homoz: homozygous; Heteroz: heterozygous. Ø: not reported in the ExAC database.  
a: paper reporting the identified mutation; b: paper describing the patient reported in the present study. 
cI, cII, cIII, cIV: complex I, II, III, IV defect; mtDNA depl mtDNA depletion; multi: multiple RC complex defect; PDH: pyruvate dehydrogenase complex 
deficiency.  





Table 2: Patients analyzed by WES 
Code Biochemical defect Gene Mutations 
Exonic 




NGSP67 multi PC p.N647D homoz / AR 
Consanguineous parents;            
1 homozygous affected 
sister 
Ø   
NGSP73 cIV "COA-X" compound heteroz / AR Consanguineous parents: heterozygous Ø   
NGSP65 PDH CYP2U1 c.1283_1288+8del / AR Consanguineous parents: heterozygous Ø   
NGSP66 cIV PREPL / ex.6-14 AR Consanguineous parents     
NGSP110 multi RANBP2 p.T585M / AD "Affected" mother: heterozygous <0,01% [46] 
Probably pathogenic variants 
NGSP91 PDH E4F1  p.K144Q / AR 
Parents: heterozygous;  
1 homozygous affected 
brother 
<0,01%   
Unsolved WES cases 
NGSP47 mtDNA depl TRMT1 p.N70S+p.A171V / AR 
1 affected sibling. Variants 
on the same allele 0,1%; Ø   
NGSP49 Neg TENM4 p.N1799H+p.Q2527K / AR 
2 affected sibling. Variants 
on the same allele 0,2%; 0,2%   
NGSP89 PDH GNAO1 p.D134N+p.A165V / AR Different phenotype Ø   
NGSP116 multi MRS2 p.R446H homoz / AR Consanguineous parents 0,33%   
AR: autosomal recessive; AD: autosomal dominant. Homoz: homozygous; Heteroz: heterozygous. Ø: not reported in the ExAC database.  
"COA-X": gene coding for a putative assembly factor specific to complex IV. cIV: complex IV defect; mtDNA depl mtDNA depletion; multi: multiple 
RC complex defect; PDH: pyruvate dehydrogenase complex deficiency. Neg: patient without biochemical deficits 
